Processa Pharmaceuticals, Inc. - Common Stock (PCSA)
0.4789
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 9th, 8:16 AM EDT
Detailed Quote
Previous Close
0.4789
Open
-
Bid
0.3641
Ask
0.3694
Day's Range
N/A - N/A
52 Week Range
0.1500 - 1.500
Volume
4,271,363
Market Cap
24.11M
PE Ratio (TTM)
-0.2064
EPS (TTM)
-2.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
18,650,352
Chart
About Processa Pharmaceuticals, Inc. - Common Stock (PCSA)
Processa Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of innovative therapeutic solutions for patients with unmet medical needs. The company primarily concentrates on advancing treatments for various cancer types and gastrointestinal disorders by utilizing its proprietary drug candidates. Through rigorous research and clinical trials, Processa aims to improve patient outcomes and enhance the quality of life for those affected by serious health conditions. Its strategic approach includes leveraging repurposed existing therapies as well as developing novel compounds, highlighting its commitment to addressing significant healthcare challenges. Read More
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Stay updated with the latest market activity on Tuesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
A recent CDC investigation confirmed 17 Listeria cases across 13 U.S. states, including 16 hospitalizations and three deaths , linked to FreshRealm chicken fettuccine Alfredo meals sold under Walmart’s Marketside and Kroger’s Home Chef brands. The outbreak underscores growing vulnerabilities in the ready-to-eat (RTE) food sector, where contamination inside production facilities can bypass consumer safeguards and trigger large-scale recalls, lawsuits, and brand damage.
Peraso Inc. (NASDAQ: PRSO) a fundamental growth story —driven by military contracts, commercial wins, and sector diversification—is even more compelling. Over the past year, Peraso has strategically expanded its footprint, building a foundation for long-term growth powered by its proprietary 60 GHz mmWave technology .
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.
ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, July 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
